TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

BACKGROUND: TLE3, a nuclear transcriptional repressor downstream of WNT signalling pathways, has been hypothesised as predictive of benefit from adjuvant taxane. METHODS: MA.21 tissue microarrays were constructed from 1097 out of 2104 (52%) patients. TLE3 staining by immunohistochemistry used valida...

詳細記述

保存先:
書誌詳細
出版年:Br J Cancer
主要な著者: Bartlett, J M S, Nielsen, T O, Gao, D, Gelmon, K A, Quintayo, M A, Starczynski, J, Han, L, Burnell, M J, Levine, M N, Chen, B E, Shepherd, L E, Chapman, J W
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2015
主題:
Translational Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559832/
https://ncbi.nlm.nih.gov/pubmed/26284338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.271
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料